Current trends in the management of ocular symptoms in Adamantiades-Behçet’s disease

Fouad R Zakka,1 Peter Y Chang,1 Gian P Giuliari,1 C Stephen Foster1,21Massachusetts Eye Research and Surgery institution (MERSI), Cambridge, Massachusetts, USA; 2Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USAAbstract: Adamantiades-Behçet&a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Fouad R Zakka, Peter Y Chang, Gian P Giuliari, C Stephen Foster
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2009
Materias:
Acceso en línea:https://doaj.org/article/2b3d89f0b8514d928406a351adba3adc
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:2b3d89f0b8514d928406a351adba3adc
record_format dspace
spelling oai:doaj.org-article:2b3d89f0b8514d928406a351adba3adc2021-12-02T01:52:31ZCurrent trends in the management of ocular symptoms in Adamantiades-Behçet’s disease1177-54671177-5483https://doaj.org/article/2b3d89f0b8514d928406a351adba3adc2009-10-01T00:00:00Zhttp://www.dovepress.com/current-trends-in-the-management-of-ocular-symptoms-in-adamantiades-be-a3640https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Fouad R Zakka,1 Peter Y Chang,1 Gian P Giuliari,1 C Stephen Foster1,21Massachusetts Eye Research and Surgery institution (MERSI), Cambridge, Massachusetts, USA; 2Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USAAbstract: Adamantiades-Behçet’s disease (ABD) is a multisystemic vasculitic disease. It is most prevalent in the Eastern Mediterranean countries and the Eastern region of Asia. Its effect on the eye can range from mild to debilitating, resulting in total blindness. A necrotizing and obliterative vasculitis affects both arteries and veins of organs. Recurrent attacks of uveitis, oral aphthous ulcers, skin lesions, and genital ulcers are common. Topical and systemic corticosteroids have been the mainstay in the treatment of ocular inflammation for many years; however, due to the several known side effects of corticosteroids and thanks to scientific advances, more novel approaches to ABD treatment have been emerging. Antimetabolites such as methotrexate and azathioprine have been utilized with the latter showing positive results. Chlorambucil has been utilized effectively for ocular manifestations of ABD. Interferon alpha has shown encouraging results in the management of refractory ocular inflammation associated with ABD, either alone or in combination with other immunosuppressive agents. Surgical interventions to deal with complications from ABD can be safely done if adequate control of inflammation is achieved peri-operatively. Early detection and aggressive treatment, when needed, have proven to be essential in the management of this relentlessly explosive disease.Keywords: Adamantiades-Behçet’s disease, Behçet’s disease, ocular inflammation, uveitis, immunomodulatory therapy, immunosuppressive therapy Fouad R ZakkaPeter Y ChangGian P GiuliariC Stephen FosterDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2009, Iss default, Pp 567-579 (2009)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Fouad R Zakka
Peter Y Chang
Gian P Giuliari
C Stephen Foster
Current trends in the management of ocular symptoms in Adamantiades-Behçet’s disease
description Fouad R Zakka,1 Peter Y Chang,1 Gian P Giuliari,1 C Stephen Foster1,21Massachusetts Eye Research and Surgery institution (MERSI), Cambridge, Massachusetts, USA; 2Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USAAbstract: Adamantiades-Behçet’s disease (ABD) is a multisystemic vasculitic disease. It is most prevalent in the Eastern Mediterranean countries and the Eastern region of Asia. Its effect on the eye can range from mild to debilitating, resulting in total blindness. A necrotizing and obliterative vasculitis affects both arteries and veins of organs. Recurrent attacks of uveitis, oral aphthous ulcers, skin lesions, and genital ulcers are common. Topical and systemic corticosteroids have been the mainstay in the treatment of ocular inflammation for many years; however, due to the several known side effects of corticosteroids and thanks to scientific advances, more novel approaches to ABD treatment have been emerging. Antimetabolites such as methotrexate and azathioprine have been utilized with the latter showing positive results. Chlorambucil has been utilized effectively for ocular manifestations of ABD. Interferon alpha has shown encouraging results in the management of refractory ocular inflammation associated with ABD, either alone or in combination with other immunosuppressive agents. Surgical interventions to deal with complications from ABD can be safely done if adequate control of inflammation is achieved peri-operatively. Early detection and aggressive treatment, when needed, have proven to be essential in the management of this relentlessly explosive disease.Keywords: Adamantiades-Behçet’s disease, Behçet’s disease, ocular inflammation, uveitis, immunomodulatory therapy, immunosuppressive therapy
format article
author Fouad R Zakka
Peter Y Chang
Gian P Giuliari
C Stephen Foster
author_facet Fouad R Zakka
Peter Y Chang
Gian P Giuliari
C Stephen Foster
author_sort Fouad R Zakka
title Current trends in the management of ocular symptoms in Adamantiades-Behçet’s disease
title_short Current trends in the management of ocular symptoms in Adamantiades-Behçet’s disease
title_full Current trends in the management of ocular symptoms in Adamantiades-Behçet’s disease
title_fullStr Current trends in the management of ocular symptoms in Adamantiades-Behçet’s disease
title_full_unstemmed Current trends in the management of ocular symptoms in Adamantiades-Behçet’s disease
title_sort current trends in the management of ocular symptoms in adamantiades-behçet’s disease
publisher Dove Medical Press
publishDate 2009
url https://doaj.org/article/2b3d89f0b8514d928406a351adba3adc
work_keys_str_mv AT fouadampnbsprzakka currenttrendsinthemanagementofocularsymptomsinadamantiadesbehampccediletamprsquosdisease
AT peterychang currenttrendsinthemanagementofocularsymptomsinadamantiadesbehampccediletamprsquosdisease
AT gianpgiuliari currenttrendsinthemanagementofocularsymptomsinadamantiadesbehampccediletamprsquosdisease
AT cstephenfoster currenttrendsinthemanagementofocularsymptomsinadamantiadesbehampccediletamprsquosdisease
_version_ 1718402822994657280